sunday 23 sEpTEMbEr - ehmtic 2012

EHMTIC20I2
European Headache and Migraine Trust International Congress
Poster Programme
contInued
late BreakIng aBstracts
lB01 Nitric oxide synthase, Calcitonin Gene-Related Peptide and inflammatory mechanisms are involved in GTN
induced neuronal activation.
Ramachandran, R.; Bhatt, K.; Jansen-Olesen, I.; Olesen, J.
Glostrup Hospital, Denmark
lB02 High frequency headache prevalence and management in primary care. A survey among general practitioners
of the Liege area, Belgium.
Magis, D; Schoenen, J
Headache Research Unit - University Department of Neurology, Liege, Belgium
lB03 Short term improvement of migraine headaches during ketogenic diet: a prospective observational study in a
dietician clinical setting.
Di Lorenzo, C. 1 ; Coppola, G. 2 ; Sirianni, G. 3 ; Pierelli, F. 1
1 2 Sapienza University of Rome, Italy; G.B. Bietti Foundation-IRCCS, Dept of Neurophysiology of Vision and Neurophthalmology,
Rome, Italy; 3Wellness and Dietary Medicine, Krom Genetics Institute, Rome, Italy
lB04 Changes in clinical migraine picture and in headache frequency in adolescence. Three year prospective study
Kalashyan, R
Arabkir Medical Center, Armenia
lB05 First demonstration of the neuroimmune link in humans using IV Endotoxin and Intradermal Capsaicin in the
face and arm
Rolan, P.E. 1 ; Hutchinson, M.R. 1 ; Buijs, M. 2 ; Tuke, J. 1 ; Kwok, Y.H. 1 ; Gentgall, M. 1 ; Williams, D. 3 ; Nillsen, N. 1
1 2 3 University of Adelaide, Australia; University of Leiden, Netherlands; University of South Australia, Australia
lB06 Post market pilot programme with single pulse transcranial magnetic stimulation (sTMS) for acute treatment
of migraine: SpringTMS use in migraine
Weatherall, M.W. 1 ; Bhola, R. 2 ; Giffin, N. 3 ; Goadsby, P.J. 4
1 2 3 Princess Margaret Migraine Clinic, London, United Kingdom; eNeura Therapeutics, California, United States; Royal United
Hospital, Bath, United Kingdom; 4UCSF, San Francisco, United States
lB07 Role of Psychiatric disorders in association of headache and temporomandibular disorders
Nazeri, M; Abareghi, F
Medical Students Research Committee, Medical Sciences University, Kerman, Iran
lB08 PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act
centrally to achieve clinical efficacy
Vermeersch, S.G.G. 1 ; de Hoon, J. 1 ; De Saint-Hubert, B. 1 ; Derdelinckx, I. 1 ; Serdons, K. 2 ; Bormans, G. 3 ;
Reynders, T. 4 ; Declercq, R. 4 ; De Lepeleire, I. 4 ; Kennedy, W. 5 ; Blanchard, R. 5 ; Marcantonio, E. 5 ; Hargreaves,
R. 6 ; Li, C.C. 6 ; Sanabria, S. 6 ; Hostetler, E. 6 ; Joshi, A. 6 ; Evelhoch, J. 6 ; Van Laere, K. 2
1 2 Center for Clinical Pharmacology, Campus Gasthuisberg, University Hospitals Leuven (KU Leuven), Leuv, Belgium; Nuclear
Medicine Department, UZ and KU Leuven, Belgium; 3Laboratory for Radiopharmacy, KU Leuven, Belgium; 4Merck Sharp & Dohme
(Europe) Inc., Brussels, Belgium; 5Merck Research Laboratories, Upper Gwynedd PA, United States; 6Merck Research Laboratories,
West Point PA, United States
lB09 Facial spasm and headaches: Should we call it “IIH-Spasm syndrome?”
Muzerengi, S; Moor, C; Davies, M
University Hospital of North Staffordshire NHS trust, United Kingdom
61